{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:31:49Z","timestamp":1760549509244},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>This matched-paired analysis explores disparities in health-related quality of life (QOL) and common toxicities between African American (AA) and white patients following proton therapy for prostate cancer at our institution.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>A total of 1536 men with clinically localized prostate cancer were treated from 2006 to 2009 with definitive proton therapy to a median dose of 78 Gy +\/\u2212 androgen deprivation therapy. A cohort of 92 consecutively treated AA men was matched to a cohort of 92 white men on the basis of National Comprehensive Cancer Network risk category and age. The 2 groups were compared with regard to comorbidities, demographics, and treatment regimen. Differences in genitourinary and gastrointestinal (GI) toxicity according to the Common Terminology Criteria for Adverse Events scale and QOL data from the Expanded Prostate Index Composite 26-question questionnaire were reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Median follow-up was 2.1 years. Baseline patient and treatment characteristics were similar between the 2 groups with the exception of prostate-specific antigen \u226510 (32% for AAs vs. 20% for whites; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.068) and use of androgen deprivation therapy (26% for AAs vs. 21% for whites; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.38). No difference in Expanded Prostate Index Composite 26-question sexual summary, urinary incontinence, urinary obstruction, or bowel summary scores was detected between the 2 groups, nor was there a difference in grade 2 or higher GI toxicity (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.45). AAs had a statistically nonsignificant higher absolute incidence of late grade 3 genitourinary toxicity (4.4% vs. 0%; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.12).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>After 2 years, there were no disparities in health-related QOL, physician-reported Common Terminology Criteria for Adverse Events GI toxicity, or biochemical relapse. Longer follow-up is needed to confirm these findings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000050","type":"journal-article","created":{"date-parts":[[2014,4,14]],"date-time":"2014-04-14T16:22:22Z","timestamp":1397492542000},"page":"261-265","source":"Crossref","is-referenced-by-count":9,"title":["Does Race Influence Health-related Quality of Life and Toxicity Following Proton Therapy for Prostate Cancer?"],"prefix":"10.1097","volume":"39","author":[{"given":"Curtis","family":"Bryant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy P.","family":"Mendenhall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randal H.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romaine C.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William M.","family":"Mendenhall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher G.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradford S.","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2003.01.199","article-title":"Time course and predictors of symptoms after primary prostate cancer therapy","volume":"21","author":"Talcott","year":"2003","journal-title":"J Clin Oncol"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of life and satisfaction with outcome among prostate-cancer survivors","volume":"358","author":"Sanda","year":"2008","journal-title":"N Engl J Med"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0022-5347(05)68578-3","article-title":"Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies","volume":"162","author":"Catalona","year":"1999","journal-title":"J Urol"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0022-5347(01)65488-0","article-title":"Risk factors for urinary incontinence after radical prostatectomy","volume":"156","author":"Eastham","year":"1996","journal-title":"J Urol"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.urology.2005.11.019","article-title":"Ethnicity and determinants of quality of life after prostate cancer treatment","volume":"67","author":"Penedo","year":"2006","journal-title":"Urology"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.urology.2010.03.087","article-title":"Comprehensive quality-of-life outcomes in the setting of a multidisciplinary, equal access prostate cancer clinic","volume":"76","author":"Rice","year":"2010","journal-title":"Urology"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jama.2011.1333","article-title":"Prediction of erectile function following treatment for prostate cancer","volume":"306","author":"Alemozaffar","year":"2011","journal-title":"JAMA"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1001\/jama.283.3.354","article-title":"Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study","volume":"283","author":"Stanford","year":"2000","journal-title":"JAMA"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0090-4295(99)00436-7","article-title":"Prostate cancer biochemical recurrence stage for stage is more frequent among African-American than white men with locally advanced but not organ-confined disease","volume":"55","author":"Powell","year":"2000","journal-title":"Urology"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1002\/cncr.26183","article-title":"Impact of race on biochemical disease recurrence after prostate brachytherapy","volume":"117","author":"Yamoah","year":"2011","journal-title":"Cancer"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1016\/j.ijrobp.2011.02.022","article-title":"Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate","volume":"81","author":"Winkfield","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.brachy.2003.11.003","article-title":"Efficacy of brachytherapy for prostate cancer in African Americans compared with Caucasians","volume":"3","author":"Barrett","year":"2004","journal-title":"Brachytherapy"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1002\/cncr.27398","article-title":"Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger","volume":"118","author":"Hoppe","year":"2012","journal-title":"Cancer"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.ijrobp.2010.12.025","article-title":"Proton radiotherapy for prostate cancer is not associated with post-treatment testosterone suppression","volume":"82","author":"Nichols","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.2009.25.8475","article-title":"Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group\/American College of Radiology 95-09","volume":"28","author":"Zietman","year":"2010","journal-title":"J Clin Oncol"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijrobp.2010.09.024","article-title":"Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer","volume":"82","author":"Mendenhall","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1001\/jama.2012.460","article-title":"Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer","volume":"307","author":"Sheets","year":"2012","journal-title":"JAMA"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1200\/JCO.2005.05.2530","article-title":"Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy","volume":"24","author":"Peeters","year":"2006","journal-title":"J Clin Oncol"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"J Clin Oncol"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3109\/0284186X.2012.744467","article-title":"Outcomes in men with large prostates (>\/= 60 cm(3)) treated with definitive proton therapy for prostate cancer","volume":"52","author":"McGee","year":"2013","journal-title":"Acta Oncol"},{"key":"R21-20230903","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/COC.0b013e3182208262","article-title":"Differences in disease presentation, treatment outcomes, and toxicities in African American patients treated with radiation therapy for prostate cancer","volume":"35","author":"Shah","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ijrobp.2007.07.2335","article-title":"Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer","volume":"70","author":"Vargas","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000421-201606000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T03:00:48Z","timestamp":1693710048000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201606000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000050","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}